GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

HAE · Mar 28, 2026

HAEMONETICS CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000313143-26-000050General Corporate
Debt relative to revenue25thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.debt_to_revenue

92.94% · OPTIONAL · VALID

Capex intensity63thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.46% · OPTIONAL · VALID

Operating cash generation75thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

21.98% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-1.97% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure0thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

22.97% · OPTIONAL · VALID

Gross margin63thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.gross_margin

59.04% · CORE · VALID

Operating margin0thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

11.75% · CORE · VALID

R&D intensity38thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

4.48% · OPTIONAL · VALID

SBC intensity88thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2.54% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building
Mar 30, 20240/8 normalizedLevel 3Jun 29, 20240/8 normalizedLevel 3Sep 28, 20240/8 normalizedLevel 3Dec 28, 20240/8 normalizedLevel 3Mar 29, 20250/9 normalizedLevel 3Jun 28, 20250/9 normalizedLevel 3Sep 27, 20250/9 normalizedLevel 3Dec 27, 20250/9 normalizedLevel 3Mar 28, 20268/9 normalizedLevel 3Jun 27, 20268/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
361.31%
Current
92.94%
Delta
-268.38%
Capex Intensity Increased
Previous
1.87%
Current
2.46%
Delta
0.58%
Cash Generation Decreased
Previous
27.60%
Current
21.98%
Delta
-5.62%
Growth Increased
Previous
-2.75%
Current
-1.97%
Delta
0.78%
Inventory Pressure Decreased
Previous
94.75%
Current
22.97%
Delta
-71.79%
Margin Decreased
Previous
59.71%
Current
59.04%
Delta
-0.67%
Profitability Decreased
Previous
19.88%
Current
11.75%
Delta
-8.13%
R And D Intensity Increased
Previous
4.19%
Current
4.48%
Delta
0.29%
Sbc Intensity Increased
Previous
2.30%
Current
2.54%
Delta
0.23%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Has State · HAEMONETICS CORP →Transitioned To · HAE Fundamental State →Transitioned To · HAE BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · HAE CAPEX_INTENSITY_INCREASED →Transitioned To · HAE CASH_GENERATION_DECREASED →Transitioned To · HAE GROWTH_INCREASED →Transitioned To · HAE INVENTORY_PRESSURE_DECREASED →Transitioned To · HAE MARGIN_DECREASED →Transitioned To · HAE PROFITABILITY_DECREASED →Transitioned To · HAE R_AND_D_INTENSITY_INCREASED →Transitioned To · HAE SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.